Emmanuel Elalouf
Chief Operating Officer at Pangea Therapeutics Ltd.
Profile
Emmanuel Elalouf is currently the Chief Operating Officer at Pangea Therapeutics Ltd.
Previously, he worked as the Chief Operating Officer and VP-Business Development at Vascular Biogenics Ltd.
He holds an MBA from Northwestern University and a doctorate from Université Paris 1 Panthéon-Sorbonne.
Emmanuel Elalouf active positions
Companies | Position | Start |
---|---|---|
Pangea Therapeutics Ltd.
Pangea Therapeutics Ltd. Medical/Nursing ServicesHealth Services Pangea Therapeutics Ltd. is an Israeli company that specializes in developing a proprietary tumor intelligence platform called Technology Enlight. The company is based in Tel Aviv, Israel. This platform enables a deeper understanding of how a tumor would respond to therapy by considering expression abnormalities, which are more common than actionable mutations. By combining these with tumor vulnerability maps, the platform uncovers many more clinically relevant insights than approaches based solely on genomic alterations. The company was founded by Eytan Ruppin, Eyal Gottlieb, Ze'ev Ronai. The CEO is Tuvik Beker. | Chief Operating Officer | - |
Former positions of Emmanuel Elalouf
Companies | Position | End |
---|---|---|
NOTABLE LABS, LTD. | Chief Operating Officer | - |
Training of Emmanuel Elalouf
Northwestern University | Masters Business Admin |
Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Vascular Biogenics Ltd.
Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
Pangea Therapeutics Ltd.
Pangea Therapeutics Ltd. Medical/Nursing ServicesHealth Services Pangea Therapeutics Ltd. is an Israeli company that specializes in developing a proprietary tumor intelligence platform called Technology Enlight. The company is based in Tel Aviv, Israel. This platform enables a deeper understanding of how a tumor would respond to therapy by considering expression abnormalities, which are more common than actionable mutations. By combining these with tumor vulnerability maps, the platform uncovers many more clinically relevant insights than approaches based solely on genomic alterations. The company was founded by Eytan Ruppin, Eyal Gottlieb, Ze'ev Ronai. The CEO is Tuvik Beker. | Health Services |
- Stock Market
- Insiders
- Emmanuel Elalouf